Low IgG levels against diphtheria and tetanus both in children and in individuals over 60 years of age are demonstrated, which may be an argument for rescheduling of the DTP booster in the CIP and for including DTP vaccines in the adult vaccination program.
Abstract
Childhood immunisation programs (CIP) have led to a substantial reduction in vaccine preventable diseases. However, simply monitoring a decline in disease incidence does not accurately reflect an individual's immunity to each disease. To identify the immune status in the Norwegian population, we measured the IgG levels against antigens of 7 vaccine preventable diseases (diphtheria, tetanus, pertussis (DTP), measles, mumps, rubella and Hemophilus influenzae type b infection) in 3051 residual sera representative of the Norwegian population aged 2-95 years in 2012. We found that 39.8% of women and 25.0% of men born before the launch of the CIP in 1952 (i.e. ≥60 years) had IgG antibody levels below the protective threshold for diphtheria, and 76.5% and 41.7% for tetanus, respectively. Among children, 20.7% had low IgG levels against diphtheria and 25.0% had low levels against tetanus at age six years, prior to the DTP booster dose at age seven. When we applied a suggested cutoff for protection of 5 IU/ml for IgG antibodies against pertussis toxin, 76.4% of children aged 6 years fell below this level, as did about 53.3% of teenagers aged 16 years, and 32.3% of individuals aged 60 year or older. For measles and rubella, we found adequate levels of IgG in all age groups, whereas IgG levels against mumps were close to a suggested threshold for protection. The highest IgG levels for measles, mumps and rubella were observed in adults from the age of 40 years, most of whom have likely experienced the diseases and have probably never been vaccinated. In conclusion, we demonstrate low IgG levels against diphtheria and tetanus both in children and in individuals over 60 years of age. Our findings may be an argument for rescheduling of the DTP booster in the CIP and for including DTP vaccines in the adult vaccination program.
The author briefly summarizes her experience with an interactive, although short-lived, educational website addressing varicella disease burden and prevention, highlighting frequently asked questions and common misconceptions related to varicella-zoster infections in Hungary.
BACKGROUND
Vaccination coverage estimates and case-based surveillance have limitations in evaluating immunization programs. Serosurveillance offers a complementary approach by directly measuring population immunity. We assessed whether serologic analyses across multiple antigens (i.e., measles, diphtheria, tetanus) cou...
A. Sbarra, Simon Mutembo, A. Carcelen et al.· Vaccine· 0 citations
Subunit vaccines against classical swine fever (CSF) have been proposed as a safer alternative to modified live vaccines. Porvac®, based on the chimeric protein E2-CD154 (fusion of CSFV E2 glycoprotein and CD154), was registered in Cuba in 2017. This study reports seven years of Porvac® use in the Isle of Youth. In Nov...
Yusmel Sordo-Puga, Talía Sardina-González, D. Pérez-Pérez et al.· Vaccine· 0 citations
Regression analyses showed that there was a 2·5-times increase in the odds of vaccinated children having increased pneumococcal density 14 days later, compared with that in unvaccinated children, and a 2·0-times increase in the odds of S pneumoniae acquisition in household members after administering LAIV.
J. Metz, George Qian, B. Morales-Aza et al.· The Lancet Microbe· 0 citations
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections in young children. In 2019, RSV was estimated to cause approximately 33 million acute lower respiratory infections, 3.6 million hospitalisations and more than 101,000 deaths among children under five years of age, with more than...
A significant measles immunity gap exists among younger adults in Türkiye, with Measles IgG seropositivity declining from 78.4% in 2014–2019 to 62.6% in 2022, consistent with a cohort effect whereby vaccine-era cohorts exhibit lower protection than older adults with naturally acquired immunity.
Kutay Sarsar, Ismail Aytaç Acar, S. Meşe et al.· Medicina· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.